Sarah Elizabeth Taylor

Dr. Sarah Elizabeth Taylor

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SBShoumei Bai
Shoumei Bai
STSarah Elizabeth Taylor
Sarah Elizabeth Taylor
MJMohd Azrin Jamalruddin
Mohd Azrin Jamalruddin
SMStacy McGonigal
Stacy McGonigal
EGEdward Grimley
Edward Grimley
Ronald BuckanovichRonald Buckanovich
Ronald Buckanovich
Approximately 20% of high-grade serous ovarian cancers (HGSOC) have CCNE1 amplification. CCNE1-amplified tumors are homologous recombination (HR) proficient and resistant to standard therapies. Therapy resistance is associated with increased numbers of polyploid giant cancer cells (PGCC). We sought to identify new therapeutic approaches for patients with CCNE1-amplified tumors. Using TCGA data, we find that the mTOR, HR, and DNA checkpoint pathways are enriched in CCNE1-amplified ovarian cancers. Furthermore, Interactome Mapping Analysis linked the mTOR activity with upregulation of HR and DNA checkpoint pathways. Indeed, we find that mTOR inhibitors (mTORi) downregulate HR/checkpoint genes in CCNE1-amplified tumors. As CCNE1-amplified tumors are dependent on the HR pathway for viability, mTORi proved selectively effective in CCNE1-amplified tumors. Similarly, via downregulation of HR genes, mTORi increased CCNE1-amplifed HGSOC response to PARPi. In contrast, overexpression of HR/checkpoint proteins (RAD51 or ATR), induced resistance to mTORi. In vivo, mTORi alone potently reduced CCNE1-amplified tumor growth and the combination of mTORi and PARPi increased response and tumor eradication. Tumors treated with mTORi demonstrated a significant reduction in ALDH+ PGCCs. Finally, as a proof of principle, we identified three patients with CCNE1 amplified tumors who were treated with an mTORi. All three obtained clinical benefits from the therapy. Our studies and clinical experience indicate mTORi are a potential therapeutic approach for patients with CCNE1-amplified tumors.

1 January 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
STSarah Elizabeth Taylor
Sarah Elizabeth Taylor
TCTianjiao Chu
Tianjiao Chu
JEJulia A. Elvin
Julia A. Elvin
RERobert P. Edwards
Robert P. Edwards
KZKristin K. Zorn
Kristin K. Zorn

5 June 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FSFlurina Annacarina Maria Saner
Flurina Annacarina Maria Saner
KTKazuaki Takahashi
Kazuaki Takahashi
TBTimothy Budden
Timothy Budden
APAhwan Pandey
Ahwan Pandey
DADinuka Ariyaratne
Dinuka Ariyaratne
DGDale W. Garsed
Dale W. Garsed
Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences survival in tubo-ovarian high-grade serous carcinoma (HGSC). Experimental Design: RB1 protein expression was classified by immunohistochemistry in ovarian carcinomas of 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined RB1 expression and germline BRCA status in a subset of 1,134 HGSC, and related genotype to overall survival (OS), tumor-infiltrating CD8+ lymphocytes, and transcriptomic subtypes. Using CRISPR-Cas9, we deleted RB1 in HGSC cells with and without BRCA1 alterations to model co-loss with treatment response. We performed whole-genome and transcriptome data analyses on 126 patients with primary HGSC to characterize tumors with concurrent BRCA deficiency and RB1 loss. Results: RB1 loss was associated with longer OS in HGSC but with poorer prognosis in endometrioid ovarian carcinoma. Patients with HGSC harboring both RB1 loss and pathogenic germline BRCA variants had superior OS compared with patients with either alteration alone, and their median OS was three times longer than those without pathogenic BRCA variants and retained RB1 expression (9.3 vs. 3.1 years). Enhanced sensitivity to cisplatin and paclitaxel was seen in BRCA1-altered cells with RB1 knockout. Combined RB1 loss and BRCA deficiency correlated with transcriptional markers of enhanced IFN response, cell-cycle deregulation, and reduced epithelial–mesenchymal transition. CD8+ lymphocytes were most prevalent in BRCA-deficient HGSC with co-loss of RB1. Conclusions: Co-occurrence of RB1 loss and BRCA deficiency was associated with exceptionally long survival in patients with HGSC, potentially due to better treatment response and immune stimulation.

1 May 2022 in JCO Precision Oncology
Verified
Journal Article
Closed access
MCMegan A. Czekalski
Megan A. Czekalski
RHRachelle C. Huziak
Rachelle C. Huziak
ADAndrea L Durst
Andrea L Durst
STSarah Elizabeth Taylor
Sarah Elizabeth Taylor
PMPhuong L. Mai
Phuong L. Mai
PURPOSE: With limitations in early detection and poor treatment response, ovarian cancer is associated with significant morbidity and mortality. Up to 25% of epithelial ovarian cancer (EOC) is related to a hereditary predisposition. Current National Comprehensive Cancer Network guidelines recommend that all individuals diagnosed with EOC be offered germline genetic testing. Although this would ideally be performed by genetics professionals, a shortage of genetic counselors can affect timely access to these services. This study sought to investigate the current genetic testing practices of oncology providers to determine the feasibility of oncologist-led genetic testing for patients with EOC. METHODS: A survey was distributed to members of the Society of Gynecologic Oncologists with questions regarding timing, frequency, and type of cancer genetic testing, referrals to genetics professionals, confidence with aspects of genetic testing, and any barriers to these processes. RESULTS: We received 170 evaluable responses. Eighty-five percent of providers always ordered genetic testing for patients with EOC. Most providers ordered germline multigene panel testing (95.8%), generally at diagnosis (64.5%). Provider confidence with the genetic testing process was generally high and significantly differed by providers' testing practices, namely, respondents who reported always ordering genetic testing tended to be more confident in ordering testing ( P = .008), interpreting results ( P = .005), and counseling a patient ( P = .002). Patient disinterest and concerns for insurance coverage were commonly cited as barriers to testing and referrals. CONCLUSION: The findings from this study suggest that oncologist-led genetic testing for patients with EOC, with referrals to genetics professionals when appropriate, has the potential to be a viable alternative service delivery model to increase access to genetic testing for patients diagnosed with EOC.

4 January 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
TTTeresa Hagan Thomas
Teresa Hagan Thomas
PMPatty Jo Murray
Patty Jo Murray
MRMargaret Rosenzweig
Margaret Rosenzweig
STSarah Elizabeth Taylor
Sarah Elizabeth Taylor
ABAdam Brufsky
Adam Brufsky
YSYael Schenker
Yael Schenker

7 July 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
JHJulianne L. Holleran
Julianne L. Holleran
RPRobert A. Parise
Robert A. Parise
JGJianxia Guo
Jianxia Guo
BKBrian F. Kiesel
Brian F. Kiesel
STSarah Elizabeth Taylor
Sarah Elizabeth Taylor
JBJan H. Beumer
Jan H. Beumer